<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461667</url>
  </required_header>
  <id_info>
    <org_study_id>GDCRI/ACM/PG/PhD/2/2013-2014G</org_study_id>
    <nct_id>NCT02461667</nct_id>
  </id_info>
  <brief_title>Alendronate Compared to Metformin in Chronic Periodontitis</brief_title>
  <official_title>Comparative Evaluation of Subgingivally Delivered 1% Metformin and 1% Alendronate Gel in Treatment of Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Dental College and Research Institute, Bangalore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Dental College and Research Institute, Bangalore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 9 month randomised controlled clinical comparing the clinical efficacy of&#xD;
      1%metformin and 1%alendronate in chronic periodontitis subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSTRACT Background: Since Metformin (MF) induces osteoblast growth and differentiation while&#xD;
      Alendronate (ALN) act as an antiosteolytic agent. The aim of the present study is to evaluate&#xD;
      and compare the efficacy of 1% ALN and 1% MF gel as a local drug delivery system in adjunct&#xD;
      to scaling and root planing (SRP) for the treatment of intrabony defects in patients with&#xD;
      chronic periodontitis.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The study had 3 groups comprising of ninety subjects, divided into three groups 1% MF with&#xD;
      SRP, 1% ALN with SRP and placebo gel with SRP. Clinical parameters (plaque index (PI),&#xD;
      modified sulcus bleeding index (mSBI), probing pocket depth (PPD), and clinical attachment&#xD;
      level (CAL) were recorded at baseline, 3, 6 and 9 months. Radiographic parameters intrabony&#xD;
      defect depth (IBD) and defect depth reduction (DDR%) was calculated on standardized&#xD;
      radiographs by using image analysis software at 6 and 9 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone fill</measure>
    <time_frame>baseline to 9 months</time_frame>
    <description>amount of bone fill from baseline to 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative vertical clinical attachment level</measure>
    <time_frame>baseline to 9 months</time_frame>
    <description>change in Relative vertical clinical attachment level baseline to 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>probing depth</measure>
    <time_frame>baseline to 9 months</time_frame>
    <description>change in probing depth from baseline to 9 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP plus Placebo Gel</intervention_name>
    <description>After SRP, placebo gel was delivered subgingivally into the pocket</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP plus Alendronate gel</intervention_name>
    <description>Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>Alendronate gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP plus Metformin gel</intervention_name>
    <description>Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All the subjects were systemically healthy&#xD;
&#xD;
          -  subjects with sites having CAL ≥ 3 mm, PPD ≥ 5 mm,&#xD;
&#xD;
          -  vertical bone loss ≥ 3 mm on intraoral periapical radiographs (IOPA) and&#xD;
&#xD;
          -  subjects with no history of periodontal intervention in the last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with systemic diseases like cardiovascular disease&#xD;
&#xD;
          -  diabetes or HIV infection or on medications like corticosteroids which may impede the&#xD;
             healing in periodontal tissues.&#xD;
&#xD;
          -  pregnant/lactating females&#xD;
&#xD;
          -  tobacco users&#xD;
&#xD;
          -  alcoholics&#xD;
&#xD;
          -  patients with unsatisfactory oral hygiene (plaque index greater than 1.5)&#xD;
&#xD;
          -  teeth having gingival recession, caries involving pulp, intrabony defect present&#xD;
             interproximally, grade 2/3 mobility&#xD;
&#xD;
          -  Furthermore, patients allergic to Metformin and alendronate or those taking Metformin&#xD;
             and alendronate systemically were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 31, 2015</last_update_submitted>
  <last_update_submitted_qc>May 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Government Dental College and Research Institute, Bangalore</investigator_affiliation>
    <investigator_full_name>Dr. A R Pradeep</investigator_full_name>
    <investigator_title>Professor and head, Dept. of Periodontology</investigator_title>
  </responsible_party>
  <keyword>alendronate, metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

